Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.44 USD
-0.05 (-1.43%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
FULC 3.44 -0.05(-1.43%)
Will FULC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FULC
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Here's Why Investors Should Invest in Arcturus Stock Now
Other News for FULC
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy/Sell: Wall Street's top 10 stock calls this week
Goldman Sachs moves to Not Rated on Fulcrum Therapeutics after study failure